STAP Papers Retracted

Nature issues retractions of the stimulus-triggered acquisition of pluripotency papers and pens an editorial on the controversy surrounding their publication.

Written byTracy Vence
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

HARUKO OBOKATAAfter months of failed replication attempts, institutional investigations, findings of research misconduct, and several calls for retractions, RIKEN’s Haruko Obokata and her colleagues today (July 2) pulled both of their stimulus-triggered acquisition of pluripotency (STAP) studies. Also retracted was Austin Smith’s News and Views article, which accompanied the two STAP papers when they were published in Nature in January. Smith, a stem-cell researcher from the University of Cambridge, wrote in a Nature notice that his comments were “based on the accuracy and reproducibility of [Obokata and her colleagues’] data.”

In an editorial published today, the journal’s editors said they had verified that STAP was independently replicated in the coauthors’ labs before publishing the studies, and that reviewers of the work “could not have detected the problems that fatally undermined the papers.” Rather, the editors said, Nature was misled by the studies’ authors (specifically, in their contributions statements). “The referees’ rigorous reports quite rightly took on trust what was presented in the papers,” the editors wrote.

“In short: although editors and referees could not have detected the fatal faults in this work, the episode has further highlighted flaws in Nature’s procedures and in the procedures of institutions that publish with us,” the journal’s staff concluded.

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies